SG小鸭子
2021-12-22
Ygty
BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax 计划获得纳米级 COVID-19 抗体许可后股价飙升</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691617144,"tweetId":"691617144","gmtCreate":1640183351740,"gmtModify":1640183716603,"author":{"id":3561283969704258,"idStr":"3561283969704258","authorId":3561283969704258,"authorIdStr":"3561283969704258","name":"SG小鸭子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Ygty</p></body></html>","htmlText":"<html><head></head><body><p>Ygty</p></body></html>","text":"Ygty","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691617144","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohunote.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax 计划获得纳米级 COVID-19 抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga Earnings","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与马克斯·普朗克学会和德国哥廷根大学医学中心达成协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算进行为期5年的战略研究合作，包括BiondVax授权VHH抗体的选择权。</li><li>VHH抗体由马克斯·普朗克研究所开发，与当前行业标准人单克隆抗体（mAb）相比表现出关键优势。</li><li>这些包括与更小的靶位点结合的能力、对靶的显著更高的亲和力、更高的稳定性、易于和更低的制造成本，以及提高患者安全性的潜力。</li><li>此次合作将首先授权 BiondVax 的全球独家 COVID-19 VHH 抗体候选产品。</li><li>这些候选药物已被证明可以以比当前 COVID-19 mAb 低约 100 倍的药物浓度中和所有已知的主要关注变异。</li><li>BiondVax 预计将于 2022 年完成临床前概念验证吸入研究，并于 2023 年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管不能保证双方是否以及何时会执行最终协议。</li><li><b>价格行为：</b>周三最后一次检查时，BVXV 股价在盘前交易时段上涨 98.7%，至 2.94 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax 计划获得纳米级 COVID-19 抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax 计划获得纳米级 COVID-19 抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与马克斯·普朗克学会和德国哥廷根大学医学中心达成协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算进行为期5年的战略研究合作，包括BiondVax授权VHH抗体的选择权。</li><li>VHH抗体由马克斯·普朗克研究所开发，与当前行业标准人单克隆抗体（mAb）相比表现出关键优势。</li><li>这些包括与更小的靶位点结合的能力、对靶的显著更高的亲和力、更高的稳定性、易于和更低的制造成本，以及提高患者安全性的潜力。</li><li>此次合作将首先授权 BiondVax 的全球独家 COVID-19 VHH 抗体候选产品。</li><li>这些候选药物已被证明可以以比当前 COVID-19 mAb 低约 100 倍的药物浓度中和所有已知的主要关注变异。</li><li>BiondVax 预计将于 2022 年完成临床前概念验证吸入研究，并于 2023 年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管不能保证双方是否以及何时会执行最终协议。</li><li><b>价格行为：</b>周三最后一次检查时，BVXV 股价在盘前交易时段上涨 98.7%，至 2.94 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":3477,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691617144"}
精彩评论